Plus Therapeutics

Yahoo Finance • 7 days ago

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (... Full story

Yahoo Finance • 9 days ago

D. Boral Capital Downgrades Plus Therapeutics (PSTV) to Hold

Plus Therapeutics, Inc. (NASDAQ:PSTV) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On March 31, 2026, D. Boral Capital downgraded Plus Therapeutics, Inc. (NASDAQ:PSTV) to Hold from Buy ahead of a 1-for-25 reverse stock sp... Full story

Yahoo Finance • 16 days ago

Plus Therapeutics Announces Reverse Stock Split

Plus Therapeutics Inc. HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nerv... Full story

Yahoo Finance • 2 months ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancer... Full story

Yahoo Finance • 4 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeut... Full story

Yahoo Finance • 4 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central ne... Full story

Yahoo Finance • 4 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Cohort 1 data from multiple dose ReSPECT-Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and effi... Full story

Yahoo Finance • 4 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syst... Full story

Yahoo Finance • 5 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancer... Full story

Yahoo Finance • 5 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

HOUSTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central ne... Full story

Yahoo Finance • 5 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

HOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syst... Full story

Yahoo Finance • 6 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Compan... Full story

Yahoo Finance • 7 months ago

Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. (NASDAQ:PSTV) is one of the top performers on Thursday. Shares of Plus Therapeutics soared by 39.29 percent on Thursday to finish at $0.563... Full story

Yahoo Finance • 7 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has signed a national agreement with UnitedHealthcare insurance company, a unit of UnitedHealth Group Inc. (NYSE: UNH). Effective September 15, the a... Full story

Yahoo Finance • 7 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with UnitedHealth... Full story

Yahoo Finance • 7 months ago

Plus Therapeutics receives $1.9M CPRIT payment for cancer program

* Plus Therapeutics (NASDAQ:PSTV [https://seekingalpha.com/symbol/PSTV]) on Monday said that it received a $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT). * This $1.9 million payment is... Full story

Yahoo Finance • 7 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT   

Non-dilutive payment is part of $17.6 million award granted for the Company’s leptomeningeal cancer targeted radiotherapeutic development program HOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “C... Full story

Yahoo Finance • 7 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and Medicaid Services (CMS) under the Cli... Full story

Yahoo Finance • 7 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central n... Full story

Yahoo Finance • 8 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syst... Full story